Drug Profile
Efavirenz/lamivudine/tenofovir disoproxil fumarate tablets - Macleods Pharmaceuticals
Alternative Names: Efavirenz/tenofovir disoproxil fumarate/lamivudine tablets - Macleods Pharmaceuticals; Lamivudine/efavirenz/tenofovir disoproxil fumarate tablets - Macleods Pharmaceuticals; Lamivudine/tenofovir disoproxil fumarate/efavirenz tablets - Macleods Pharmaceuticals; Tenofovir disoproxil fumarate/efavirenz/lamivudine tablets - Macleods Pharmaceuticals; Tenofovir disoproxil fumarate/lamivudine/efavirenz tablets - Macleods PharmaceuticalsLatest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Macleods Pharmaceuticals
- Class Alkynes; Antiretrovirals; Benzoxazines; Cyclopropanes; Deoxyribonucleosides; Dideoxynucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 28 Nov 2018 Launched for HIV-1 infections (In adolescents, In adults) in USA prior November 2018 (PO) (Macleods website, November 2018)